FDA approves Sanofi's factor VIII hemophilia A drug
Sanofi nabbed an FDA approval for its new hemophilia A therapy, efanesoctocog alfa, on Wednesday evening, according to FDA documents.
The newly approved drug — which has the factor VIII focus spelled out inside its branded name, Altuviiio — works to replace the missing or defective factor VIII in hemophilia A in a once-weekly treatment. It wasn’t immediately clear Thursday morning how Sanofi plans to price the drug.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,400+ biopharma pros reading Endpoints daily — and it's free.